期刊文献+

联合检测血清肿瘤相关抗原在乳腺癌诊断中的应用

The application of combined detection serum tumor associated antigen in the diagnosis of breast cancer
下载PDF
导出
摘要 目的分析联合检测血清肿瘤相关抗原CA153、CA125、组织多肽特异性抗原(TPs)和骨桥蛋白(OPN)在乳腺癌诊断中的幄床应用价值。方法选取我院乳腺科154倒乳腺癌患者和40倒乳腺良性肿瘤患者为研究对象,所有患者全部检测血清肿瘤相关抗原(CA153、CA125、TPS、OPN),其中,CA153、CA125、TPS采用电化学发光法检测,OPN采用酶联免疫吸附试验法(EusA)检测。结果乳腺癌组与乳腺良性肿瘤组血清肿瘤相关抗原浓度比较有统计学意义(P〈0.01),CA153、CA125、TPS、OPN诊断乳腺癌的敏感性分别为:63.O%、60.4%、68.2%、64.9%;特异性分剐为:95.O%、90.O%、92.5%、92.5%。联合检测敏感性明显提高,高达96.8%。结论联合检测血清肿瘤相关抗原可明显提高乳腺癌诊断的敏感性,减少漏诊,具有重要的临床应用价值。 Objective To explore the clinical value of the combined detection including CA153, CA125, tissue polypeptide specific anti- gen (TPS) and osteopontin (OPN) in the diagnosis of breast cancer. Methods 154 cases of breast cancer patients and 40 cases of benign breast tumor patients were selected asthe object of study. The serum tumor associated antigen CA153, CA125 and TPS were detected in dec- trochemica] luminescence method, OPN were detected in enzyme linked immunosorbent assay (ELISA). Results The concentration of serum tumor associated antigen w!th breast cancer was compared with the one of breast benign, and the defference has statistical significance (p 〈 0. 01), The susceptibility of CA153, CA125, TPS, OPN in the diagnosis of breast cancer were 63% ,60.4% ,68.2% and 64.9% respectively The specificity were 95% ,90% ,92.5% and 92.5%. respectively the sensitivity of the combined detection was increased significantly, up to 96.8 %. Conclusion The combined detection of serum tumor associated antigen ean obviously improve the diagnostic sensitivity of breast cancer, decrease missed diagnosis, it has important value in clinical application.
出处 《医学检验与临床》 2012年第4期49-50,共2页 Medical Laboratory Science and Clinics
关键词 乳腺癌 血清肿瘤相关抗原 联合检测 Breast cancer The serum tumor associated antigen The combined detection
  • 相关文献

参考文献6

  • 1Degoute CS,Ray M J,Gueugniauel P T. Remifentanil Induces Consistent Controlled Hypotension in Children during Middle Ear Surgery[J].Canadian Journal of anaesthesia-Journal canadien d anesthesie,2003.270-276.
  • 2范振符,陈智周.肿瘤标志物的研究与临床应用评价[J].标记免疫分析与临床,2002,9(2):108-111. 被引量:27
  • 3Massidda B,Lonta MT,Forddi MR. Usefulness of pyridinium crosslinks and CA153 as markeers in metastatic bone breast carcinoma[J].Anticancer Research,1996.2221-2225.
  • 4叶伟民,韩焕兴,孔宪涛.肿瘤标记物CA125测定及其临床意义[J].中国免疫学杂志,1999,15(11):522-522. 被引量:20
  • 5周新;涂植光.临床生物化学和生物化学检验[M]北京:人民卫生出版社,2003448-470.
  • 6Fedarko NS,Jain A Karadag A. Elevated serum bone sialoprotein and ostepontin in colon,breast,prostate,and lung cancer[J].Clinical Cancer Research,2001.4060-4066.

二级参考文献1

  • 1范振符 巴德年.肿瘤的免疫学检测.当代免疫学技术与应用[M].北京:北京医科大学中国协和医科大学联合出版社,1998.927-948.

共引文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部